Adenosine diphosphate receptor inhibitor
Adenosine diphosphate (ADP) receptor inhibitor is a class of antiplatelet agents. These drugs inhibit some or all types of adenosine diphosphate receptors (P2Y receptors). P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose.
Inhibitors of the receptor subtype P2Y12 are one class of P2Y receptor inhibitors. These drugs include clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor, and elinogrel. These inhibitors prevent expression of glycoproteins IIb/IIIa on the platelet surface.
- Hashemzadeh, M; Goldsberry, S; Furukawa, M; Khoynezhad, A; Movahed, MR (2009). "ADP receptor-blocker thienopyridines: Chemical structures, mode of action and clinical use. A review". The Journal of invasive cardiology. 21 (8): 406–12. PMID 19652255.
- Bauer, Shawn M (2003). "ADP receptor antagonists as antiplatelet therapeutics". Expert Opinion on Emerging Drugs. 8 (1): 93–101. PMID 14610915. doi:10.1517/14728220.127.116.11.
- Michelson, AD (2009). "New P2Y12 antagonists". Current Opinion in Hematology. 16 (5): 371–7. PMID 19550317. doi:10.1097/MOH.0b013e32832ea2f2.
|This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.|